HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pseudoephedrine Tide Turns: Nonprescription Sales Return In Mississippi, Oregon Mulls Change

Executive Summary

Mississippi repeals prescription requirement for all pseudoephedrine- and ephedrine-containing drugs while also requiring retailer participation in industry-funded technology for tracking drug sales. Oregon, the only other state with PSE Rx law, is considering repealing it.

You may also be interested in...

Pseudoephedrine Safety Review Initiated In EU Over Link To Neurological Problems

Reports of posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome have triggered a European Union-wide safety review of pseudoephedrine.

Manufacturers Consider Design Changes For OTC Propylhexedrine Nasal Decongestant Inhalers

"Manufacturers are already working on possible solutions to address the concerns and will work with the Agency to implement any appropriate measures,” says CHPA senior VP  Barbara Kochanowski.

Propylhexedrine Abuse Prompts US FDA To Suggest OTC Nasal Inhaler Modifications, Smaller Size

FDA published warning against abuse of propylhexedrine, but study published in October 2020 questioned why sales of products with the ingredient aren’t limited like sales of pseudoephedrine-containing OTCs under a federal law.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts